H. pylori Screening and Treatment for Helicobacter Pylori Infection
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial focuses on detecting a stomach infection called H. pylori, which can cause gastritis, stomach ulcers, or even cancer. Participants who test positive will receive VOQUEZNA® Triple Pak®, a combination therapy for H. pylori infection, to help prevent these issues. A simple breath test identifies the infection. The trial suits adults who have not previously received H. pylori treatment and have no history of stomach cancer or severe liver or kidney problems. As a Phase 4 trial, it involves an FDA-approved treatment, aiming to understand its benefits for more patients.
Will I have to stop taking my current medications?
If you are taking any of the medications listed in the exclusion criteria, you will need to stop them to participate in the trial. These include certain heart medications, statins, and others. It's best to discuss with the trial team to see if your current medications are on the list.
What is the safety track record for VOQUEZNA® Triple Pak®?
Research has shown that VOQUEZNA® Triple Pak® was tested for safety in a study involving 675 adults treated for H. pylori infections. This treatment includes three medications: vonoprazan, amoxicillin, and clarithromycin. Most participants tolerated it well, but some experienced side effects such as headaches, changes in taste, and diarrhea.
Serious concerns arise when it interacts with other medications. For instance, taking clarithromycin with certain cholesterol-lowering drugs can lead to severe side effects. Therefore, informing the study team about any other medications being taken before starting treatment is crucial.
Overall, VOQUEZNA® Triple Pak® is considered safe for many people, but monitoring for any side effects and consulting healthcare providers if concerns arise is important.12345Why are researchers enthusiastic about this study treatment?
Unlike the standard treatment options for Helicobacter pylori infection, which often include various combinations of antibiotics and acid reducers like clarithromycin, amoxicillin, and proton pump inhibitors, VOQUEZNA® Triple Pak® is noteworthy for its comprehensive approach. This treatment combines vonoprazan, a novel potassium-competitive acid blocker, with amoxicillin and clarithromycin, offering potentially enhanced acid suppression. Researchers are excited about VOQUEZNA® because vonoprazan provides a more stable gastric environment, which may improve the effectiveness of antibiotics in eradicating H. pylori. This could lead to better treatment outcomes and reduced rates of infection recurrence.
What is the effectiveness track record for VOQUEZNA® Triple Pak® in treating H. pylori infection?
Research has shown that VOQUEZNA® Triple Pak® effectively treats Helicobacter pylori (H. pylori) infection, which participants in this trial will receive if they test positive. Studies have found that this treatment successfully eradicates the infection in about 8 out of 10 people without resistant strains, achieving an eradication rate of 80.8%. Another study reported similar results, with an eradication rate of 84.7% for non-resistant strains. The FDA has approved VOQUEZNA® Triple Pak®, confirming its effectiveness in treating this infection.678910
Who Is on the Research Team?
Shria Kumar, MD
Principal Investigator
University of Miami
Are You a Good Fit for This Trial?
This trial is for individuals at risk of stomach issues in South Florida. It's focused on finding and treating Helicobacter pylori, a stomach infection linked to gastritis, ulcers, and cancer. Participants will be screened for H. pylori and treated if positive.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants who test positive for H. pylori receive VOQUEZNA® Triple Pak® therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VOQUEZNA® Triple Pak®
Trial Overview
The study uses the PYTEST® 14C-Urea Breath Test to detect H. pylori infection. Those who test positive are then treated with VOQUEZNA® Triple Pak®, which aims to eradicate the infection and prevent related diseases.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants in this single-arm study will undergo screening for Helicobacter pylori (H. pylori) using the PYtest® 14C-Urea Capsule Breath Test. This FDA-approved, non-invasive diagnostic method involves swallowing a radiolabeled urea capsule. If gastric urease from H. pylori is present, the urea is hydrolyzed to produce carbon dioxide and ammonia. Ten minutes after ingestion, a breath sample is collected in a balloon and transferred into a collection fluid to trap the labeled carbon dioxide. The sample is analyzed using a liquid scintillation counter to determine infection status. Participants who test positive will receive VOQUEZNA® Triple Pak® therapy, dispensed by the study team at the time of diagnosis. Phathom Pharmaceuticals will supply the medications (which include complete medication package insert), but the study team hold and dispenses medications.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Miami
Lead Sponsor
Phathom Pharmaceuticals
Collaborator
NRG Oncology
Collaborator
Citations
H. pylori Treatment Study | VOQUEZNA® Triple Pak ...
A randomized, controlled, double-blind triple therapy/open-label dual therapy study that evaluated the effectiveness and safety of VOQUEZNA® Triple Pak®
Vonoprazan Triple and Dual Therapy for Helicobacter ...
Primary outcome eradication rates (nonresistant strains): vonoprazan triple therapy 84.7%, dual therapy 78.5%, vs lansoprazole triple therapy ...
Drug Trials Snapshots: VOQUEZNA TRIPLE PAK ...
The primary efficacy endpoint was H. pylori eradication rate in subjects who did not have a clarithromycin or amoxicillin-resistant strain of H.
4.
investors.phathompharma.com
investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-announces-fda-approval-reformulatedNews Release
pylori. The H. pylori eradication rate with VOQUEZNA TRIPLE PAK was 80.8% versus 68.5% with lansoprazole triple therapy in the overall study ...
Treating Helicobacter pylori Infection with Vonoprazan
Outcome: The primary endpoint was H. pylori eradication based on negative 13C-urea breath test obtained at least 4 weeks after last dose of ...
Important Safety Information | VOQUEZNA® TRIPLE PAK® ...
Serious adverse reactions can occur with VOQUEZNA TRIPLE PAK due to drug interactions of clarithromycin with colchicine, some lipid lowering agents, some ...
H. pylori Treatment | VOQUEZNA® Triple Pak® (vonoprazan ...
VOQUEZNA DUAL PAK is a co-packaged product containing vonoprazan and amoxicillin. Both products are indicated for the treatment of Helicobacter pylori infection ...
highlights of prescribing information - accessdata.fda.gov
The safety of VOQUEZNA TRIPLE PAK was evaluated in 675 adult patients (aged 20 to 82 years) in clinical trials in the United States, Europe and Japan and ...
About H. Pylori
What is H. Pylori infection? Learn about H. Pylori symptoms, how the bacteria are eradicated, and more. Please see full safety and prescribing information.
Voquezna Triple Pak (vonoprazan, amoxicillin, and ...
Overview: Voquezna Triple Pak is used to treat an infection in the stomach caused by bacteria called Helicobacter pylori (H. pylori). It ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.